NasdaqGS:ANABBiotechs
Assessing AnaptysBio (ANAB) Valuation After New Share Buyback Plan And Canceled Equity Offering
Why the new capital plan matters for AnaptysBio (ANAB)
AnaptysBio (ANAB) has put capital allocation in the spotlight, authorizing up to US$100 million in share repurchases while pulling its planned at the market follow on equity offerings.
For you as an investor, that combination removes the immediate prospect of new share issuance and signals management is opting to return capital through buybacks rather than raise fresh equity at current levels.
See our latest analysis for AnaptysBio.
These...